本帖最后由 老马 于 2013-3-13 13:43 编辑 " \! U( A: @. `$ B: [
0 k- O4 m" |" d8 s. [4 U健择（吉西他滨）+顺铂+阿瓦斯汀
# @! Z) l, e. z) ^5 x2 D Gemzar +Cisplatin + Avastin2 h( ^: a2 H& R) T8 h+ b( T2 Y
http://annonc.oxfordjournals.org/content/21/9/1804.full
$ b2 v% l- x! T2 E2 T3 f7 f3 sOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* ]" _0 V1 ?; zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 5 C( X% V h3 t$ |* i4 N0 H$ H5 C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 h, v1 T7 [5 Z/ `2 U5 n4 s$ E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 806)
$ q1 e& `; D6 y+ G4 Z
华为网盘附件：
. }' N3 ?5 {6 |【华为网盘】ava.JPG0 `: s. m+ K0 ^6 n C
|
请教一下 肺腺癌IIIC期，基因检测无
患者基本情况：63岁 起码40+年龄的吸烟史，有高血压。身体状况比较好。 因咳嗽一直不
求教：肺腺癌8年，9291耐药，脑转，
我母亲，74岁，2016年12月确诊肺腺癌，在省肿瘤医院，手术右肺叶切除，有淋巴转。
基
林根：小细胞肺癌放疗及免疫治疗常见
整理者：雨过天晴审核人：鹰版小细胞肺癌（SCLC）是一种恶性程度高、侵袭性强的肺癌亚
感慨！！！一个非常令人伤感的病例
今天有时间，可以完整的听“中国胸部肿瘤大会诊——襄阳站”的MDT直播，第一个病例让
抗癌3年从晚期癌症到成功实现癌症治
讲述者：柳廷整理者：pear2022年2月，我确诊了最凶险的晚期三阴性乳腺癌，发现时已有
显身卡
